Read Why Cantor Upgraded Aurora Cannabis Stock Cantor Fitzgerald has upgraded Aurora Cannabis Inc (NASDAQ: ACB) to Overweight from Neutral Benzinga · Jun 24, 2022
This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So Cantor assumes coverage of RAPT Therapeutics Inc (NASDAQ:RAPT) with an Overweight rating and a price target of $44 (vs. $58 previously). The analyst says the company's RPT193 (lead inflammation drug) could be a $3 billion drug in just atopic dermatitis (AD) indication, as it expects AD to outperform psoriasis. Cantor suggests that ‘193 is… Benzinga · May 25, 2022
Peak Sales Potential For This ENT-Focused Stock Is Under-Appreciated, Says Cantor Cantor initiated coverage on Lyra Therapeutics Inc (NASDAQ:LYRA) with an Overweight rating and a price target of $15 (166% upside). According to the analyst, Lyra product pipeline's peak sales potential is under-appreciated, and it expects upward earnings estimate revisions to potentially move LYRA's stock higher. LYRA is well-positioned with a portfolio of products to… Benzinga · May 25, 2022
Cannabis Analyst Advises Not To Buy WeedMaps Shares Until March Cantor Fitzgerald has issued a new report on cannabis tech platform WeedMaps (NASDAQ: MAPS), also known as WM Technology Inc. Benzinga · Jan 25, 2022